Huaxia Eye Hospital GroupLtd Past Earnings Performance
Past criteria checks 2/6
Huaxia Eye Hospital GroupLtd has been growing earnings at an average annual rate of 16.2%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 11.4% per year. Huaxia Eye Hospital GroupLtd's return on equity is 9.1%, and it has net margins of 12.9%.
Key information
16.2%
Earnings growth rate
13.4%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 11.4% |
| Return on equity | 9.1% |
| Net Margin | 12.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Expensive For A Reason? A Look At Its Intrinsic Value
Dec 23
Here's What's Concerning About Huaxia Eye Hospital GroupLtd's (SZSE:301267) Returns On Capital
Oct 28Huaxia Eye Hospital Group Co.,Ltd.'s (SZSE:301267) 43% Price Boost Is Out Of Tune With Earnings
Sep 30Huaxia Eye Hospital GroupLtd's (SZSE:301267) Conservative Accounting Might Explain Soft Earnings
Sep 04Does Huaxia Eye Hospital GroupLtd (SZSE:301267) Have A Healthy Balance Sheet?
Aug 19Huaxia Eye Hospital GroupLtd's (SZSE:301267) Dividend Is Being Reduced To CN¥0.11
Jul 12Huaxia Eye Hospital GroupLtd (SZSE:301267) Has Some Way To Go To Become A Multi-Bagger
Jun 06Analysts Just Shaved Their Huaxia Eye Hospital Group Co.,Ltd. (SZSE:301267) Forecasts Dramatically
May 01Huaxia Eye Hospital GroupLtd (SZSE:301267) Seems To Use Debt Rather Sparingly
Feb 29Revenue & Expenses Breakdown
How Huaxia Eye Hospital GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,092 | 529 | 1,076 | 61 |
| 30 Jun 24 | 4,070 | 577 | 1,054 | 66 |
| 31 Mar 24 | 4,061 | 672 | 1,027 | 72 |
| 31 Dec 23 | 4,013 | 666 | 998 | 70 |
| 30 Sep 23 | 3,813 | 674 | 933 | 75 |
| 30 Jun 23 | 3,648 | 632 | 867 | 69 |
| 31 Mar 23 | 3,355 | 552 | 786 | 56 |
| 01 Jan 23 | 3,233 | 514 | 762 | 49 |
| 30 Sep 22 | 3,297 | 516 | 762 | 47 |
| 01 Jan 22 | 3,064 | 455 | 717 | 25 |
| 30 Sep 21 | 2,998 | 445 | 675 | 22 |
| 31 Dec 20 | 2,515 | 334 | 591 | 20 |
| 31 Dec 19 | 2,456 | 218 | 682 | 19 |
| 31 Dec 18 | 2,146 | 164 | 621 | 14 |
| 31 Dec 17 | 1,543 | 78 | 495 | 11 |
Quality Earnings: 301267 has high quality earnings.
Growing Profit Margin: 301267's current net profit margins (12.9%) are lower than last year (17.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301267's earnings have grown by 16.2% per year over the past 5 years.
Accelerating Growth: 301267's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301267 had negative earnings growth (-21.4%) over the past year, making it difficult to compare to the Healthcare industry average (-5.7%).
Return on Equity
High ROE: 301267's Return on Equity (9.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Huaxia Eye Hospital Group Co.,Ltd. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yichi Zhang | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |
| Shuo Song | Citic Securities Co., Ltd. |